Questions raised on very intensive glucose lowering in type 2 diabetes

Br J Cardiol 2008;15:68-9 Leave a comment
Click any image to enlarge
Authors:

The results of two major trials of intensive glucose lowering in patients with type 2 diabetes appear to have reached different conclusions.

Advertisement
Angina - BJC Learning programme
For healthcare professionals only

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, conducted by the US National Heart, Lung, and Blood Institute (NHLBI), was stopped in February because the group being treated with intensive glucose lowering was showing a higher mortality rate than the group receiving standard treatment. But just days later, the group organising another similar trial, ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), announced that preliminary results of their study did not confirm the adverse mortality trend with intensive treatment reported from the ACCORD study.

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT